Keryx Biopharmaceuticals (NASDAQ:KERX)’s Zerenex the next best news for anemia?
Last week, Keryx Biopharmaceuticals (NASDAQ:KERX) presented more details from its Zerenex, pivotal phase-III clinical study, at the World Congress of Nephrology. The new data for this phosphate-binder continues supporting what some are saying is a game-changing treatment. It has phosphate-binding as well as significant anemia benefits and will be highly beneficial for dialysis patients.
What is anemia?
The condition in which your body doesn’t have a sufficient number of healthy red blood cells is known as anemia. RBC’s carry oxygen to tissues in the body and when the body does not get enough of oxygen, it can lead to extreme exhaustion. There are different forms of anemia, each has its own specific cause, loss of blood being the most common one. Anemia may be temporary or even long-term, and can range from being mild to severe. Fatigue, paleness of skin, fast or irregular heartbeat, shortness of breath, chest pain and incessant headaches are some of the common symptoms. Initially, anemia can be very mild and tends to go unnoticed. However, as it worsens, its symptoms become more severe.
What is Zerenex?
Zerenex is an oral compound that has a ferric iron-base. It has the capacity to bind itself to phosphate and form different non-absorbable complexes. Zerenex has successfully completed a U.S.-based Phase-III clinical program for treating hyperphosphatemia in patients suffering from end-stage renal disease. The NDA submission with the Food Drug Administration is pending and so is an MAA with the EMA. In the United States, Zerenex is also in Phase-II development for management of iron and phosphorus deficiency in anemic patients suffering from Stage3-5 chronic kidney disease that is not dependent on dialysis.
The biotech space
Investing in the biotech industry is not a simple proposition and neither is operating in one. There are numerous occasions during which binary events, such as an approval from the United States’ Food and Drug Administration or a much required capital raise is possibly the difference between not just stupendous success and utter failure, but basic survival as well. Hopefully, Zerenex will give Keryx Biopharmaceuticals (NASDAQ:KERX) the boost that every company aims to achieve with the launch of a new product.